Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
63.74(c) 62.47(c) 63.18(c) 62.63(c) 61.33 Last
1 105 950 826 520 1 676 360 2 229 610 2 194 115 Volume
-0.30% -1.99% +1.14% -0.87% -2.08% Change
More quotes
Financials (USD)
Sales 2021 69,4 M - -
Net income 2021 -562 M - -
Net Debt 2021 368 M - -
P/E ratio 2021 -15,3x
Yield 2021 -
Sales 2022 101 M - -
Net income 2022 -609 M - -
Net Debt 2022 576 M - -
P/E ratio 2022 -14,5x
Yield 2022 -
Capitalization 9 156 M 9 156 M -
EV / Sales 2021 137x
EV / Sales 2022 95,9x
Nbr of Employees 391
Free-Float 65,1%
More Financials
Company
BridgeBio Pharma, Inc. is a United States-based company, The Company discovers and develops medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561,... 
Sector
Pharmaceuticals
Calendar
06/17 | 12:00pmShareholder meeting
More about the company
Ratings of BridgeBio Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BRIDGEBIO PHARMA, INC.
06/14BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(..
GL
06/01BRIDGEBIO PHARMA  : Corporate Presentation June 2021
PU
06/01BRIDGEBIO PHARMA  : Obtains FDA Fast Track Designation for Hypoparathyroidism Tr..
MT
06/01BRIDGEBIO PHARMA, INC.  : Other Events (form 8-K)
AQ
06/01BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Tr..
GL
06/01BRIDGEBIO PHARMA  : Affiliate QED Therapeutics and Partner Helsinn Group Announc..
BU
05/31BRIDGEBIO PHARMA  : Affiliate QED Therapeutics and Partner Helsinn Group Announc..
AQ
05/28BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Annou..
GL
05/25BRIDGEBIO PHARMA  : Corporate Presentation May 2021
PU
05/21BRIDGEBIO PHARMA  : UBS Starts BridgeBio Pharma at Buy with $80 Price Target
MT
05/14BRIDGEBIO PHARMA, INC.  : Results of Operations and Financial Condition, Financi..
AQ
05/14BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(..
GL
05/14BRIDGEBIO PHARMA  : Gene Therapy Receives US FDA's Fast Track Designation
MT
05/14BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene..
GL
05/11BRIDGEBIO PHARMA, INC.  : Other Events (form 8-K)
AQ
More news
News in other languages on BRIDGEBIO PHARMA, INC.

- No features available -

More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | BBIO | US10806X1028 | MarketScreener
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 81,10 $
Last Close Price 61,33 $
Spread / Highest target 48,4%
Spread / Average Target 32,2%
Spread / Lowest Target 15,8%
EPS Revisions
Managers and Directors
NameTitle
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
BRIDGEBIO PHARMA, INC.-11.93%9 350
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939